Noile-Immune Biotech, Inc.
https://www.noile-immune.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Noile-Immune Biotech, Inc.
ASCO: AstraZeneca Achieves Eye-Catching Solid Tumor Results With 'Armored' CAR-T
Solid tumor CAR-T may succeed AZD7003 where many others have failed as the firm builds its cell therapy pipeline.
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
Targeting Solid Cancers With CAR-T: Japan’s Noile-Immune Looks To Partner Platform
Setting a strategic focus on solid cancers with its enhanced PRIME CAR-T technology, Koji Tamada, CEO of Noile-Immune, shared the Japanese bioventure's collaboration strategies and views on the next generation of cell therapies.
Banking Crisis Prompts Postponed Noile-Immune IPO, But Wider Japan Views Mixed
While the SVB and wider banking crisis has shaken VCs and bioventures in the US and Europe, Japan has mixed view on its impact and the government is keeping an eye on the situation. But one biotech has nevertheless cautiously decided to withdraw from a market listing despite Tokyo Exchange Market approval.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice